
Analytical strategies to monitor polysorbate in biotherapeutics

Christian Bell, Analytical Development, Roche

March 2018



PS20 stability and degradation pathways

PS20 quantification and characterization


PS20 degradation products

Considerations for control strategy

Polysorbate in biotherapeutics

Structure and use


- Polysorbates (PS) are widely used as surface active agents in biopharma
 - ~ 3 out of 4 biologics include polysorbate as part of their formulation
- Ability to form micelles and thus particularly preventing protein aggregation as a result of adsorption at interfaces (air/water)
- Consist of hydrophilic polyoxyethylene (POE) sorbitan linked to fatty acids by an ester bond



- Chain length and relative content of specific fatty acids is defined in pharmacopoeia
 - PS20: 40-60% Laureate, i.e. saturated C12

Polysorbate in biotherapeutics

Known degradation pathways



Ravuri et al. 2011

Auto-oxidation

Hydrolysis

peroxides aldehydes
acids ketones
n-alkanes fatty acid esters etc...

fatty acids

Potential impact on product quality

Arising free radicals can cause protein modifications

Fatty acids can form insoluble particles

PS20 stability and degradation pathways

PS20 quantification and characterization

PS20 degradation products


Considerations for control strategy

Analytical strategies for polysorbates

Quantification

- **Fluorescence Micelle Assay (FMA)**

- Relies on micelle forming ability of the surfactant
- Increase in fluorescence of NPN upon micelle formation




- **Mixed Mode HPLC with ELSD/CAD detection (MM-ELSD/CAD)**

- Mixed mode anion exchange or cation exchange column (eg Oasis MCX)
- PS20 detection using ELSD or CAD detector
- Also suitable for surfactants that do not form micelles, eg Poloxamer 188

Analytical strategies for polysorbates

Characterization

- Heterogeneity of PS20 can be further characterized using a shallow gradient RP-ELSD/CAD method (Hewitt et al. 2011)
- Method is capable of resolving mono- from poly-ester species




ID	Subspecies
F1	POE, POE isosorbide, POE sorbitan
F2	POE isosorbide monoocylate
F3	POE isosorbide monodecanylolate
F4	POE sorbitan monolaurate, POE isosorbide monolaurate, POE monolaurate, POE sorbitan monomyristate
F5	POE isosorbide monomyristate, POE monomyristate, POE sorbitan monopalmitate
F6	POE isosorbide monopalmitate, POE monopalmitate
F7	POE isosorbide monodecanoate
F8	POE sorbitan dilaurate
F9	POE sorbitan laurate/myristate, POE sorbitan dimyristate, POE sorbitan myristate/palmitate

Analytical strategies for polysorbates

Choice of method is critical to monitor PS degradation


- Since FMA relies on micelle formation, its response is not uniform across the different PS20 ester species (Lippold et al 2017)
- Main component, POE sorbitan monolaurate, only detectable w/ MM-ELSD/CAD



Analytical strategies for polysorbates

Case studies


Thermal 40°C (oxidative) Degradation



← mono-esters →
← poly-esters →

- Polyesters are degraded more readily w/ temperature stress (Auto-Oxidation)
- FMA *underestimates* PS20 content since it cannot quantify monoester species

Hydrolytic degradation (sample, control)



← mono-esters →
← poly-esters →

- Hydrolytic degradation is usually specific, i.e. either mono- or polyester are more readily degraded
- When monoesters are degraded, FMA *overestimates* true PS20 content

PS20 stability and degradation pathways

PS20 quantification and characterization

PS20 degradation products

Considerations for control strategy

PS20 stability and degradation pathways

PS20 quantification and characterization

PS20 degradation products

Considerations for control strategy

Considerations for Drug Product control strategy

Driven by process and product knowledge

- PS20 should be monitored throughout the development lifecycle of a molecule, eg during formulation studies as well as during development stability studies

No change in PS content over product shelf life

- Leverage available data from development studies
- PS20 content not part of DP release or DP stability control strategy
- Monitoring only (eg as IPC)

Significant change in PS content but no impact on Product CQAs

- Provide justification that PS is not a critical excipient (incl. assessment on impact of potential degradation products)
- PS20 content not specified for DP release and stability

Significant change in PS content and impact on product CQAs

- Include PS content for DP release and stability
- Include appropriate justification for EoSL limit incl. potential impact of PS degradation products

Doing now what patients need next